Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients

References

• Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. J Exp Med. 1953;98:583–606.
   Web of Science ®Google Scholar
• Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J Exp Med. 1963;118:121–148.
   PubMed Web of Science ®Google Scholar
• Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-Asparaginase therapy for leukemia and other malignant neoplasms. JAMA. 1967;202:116–122.
   Web of Science ®Google Scholar
• Beard MEJ, Crowther D, Galton DAG, et al. L-Asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J. 1970;1:191–195.
   Google Scholar
• Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of L-asparaginase, study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966;19:1813–1819.
   PubMed Web of Science ®Google Scholar
• Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer. 1970;25:253–278.
   PubMedGoogle Scholar
• Capizzi RL, Bertino JR, Skeel RT, et al. L-Asparaginase: clinical biochemical, pharmacological and immunological studies. Ann Intern Med. 1971;74:893–901.
   PubMed Web of Science ®Google Scholar
• Haskell CM, Canellos GP, Levental BG, Carbone PP, Serpick AA, Hansen HH. L-asparaginase toxicity. Cancer Res. 1969;29:974–975.
   PubMed Web of Science ®Google Scholar
• Haskell CM, Canellos GP, Levental BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969;281:1028–1034.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780–1786.
   PubMed Web of Science ®Google Scholar
• Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621–629.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations. The past, the present and recommendations for the future. Clin Pharmacokinet. 2005 ;44:367–393.
   PubMed Web of Science ®Google Scholar
• Fu CH, Sakamoto KM. PEG asparaginase. Expert Opin Pharmacother. 2007;8:1977–1984.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–27801.
   PubMed Web of Science ®Google Scholar
• Katarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8:994–1004.
   Web of Science ®Google Scholar
• Linker CA, Levitt LJ, O’Donnell M, Forman SF, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991;78:2814–2822.
   PubMed Web of Science ®Google Scholar
• Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003;55:1293–1302.
   PubMed Web of Science ®Google Scholar
• Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9:111–119.
   PubMed Web of Science ®Google Scholar
• Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970;25:306–320.
   PubMedGoogle Scholar
• Clarkson B, Gaynor J, Franza RB, Furth M. Recent advances in the treatment of acute lymphoblastic leukemia in adults and future prospects. Trans Am Clim Climatol Assoc. 1985;96:41–55.
   Google Scholar
• Asselin B. The three asparaginases. comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621–629.
   PubMed Web of Science ®Google Scholar
• Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981;41(11 Pt 1):4554–4558.
   PubMed Web of Science ®Google Scholar
• Ahlke E, Nowak-Gottl U, Schulze-Westhoff P. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997;96:675–681.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544–1550.
   Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 200426:333–335.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110:103–111.
   PubMed Web of Science ®Google Scholar
• Schauer P, Arlin ZA, Mertelsmann R, et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol. 1983;1:462–470.
   PubMed Web of Science ®Google Scholar
• Lister TA, Whitehouse JMA, Beard MEJ, et al. Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J. 1978;1:199–203.
   PubMed Web of Science ®Google Scholar
• Marcus RE, Catovsky D, Johnson SA, et al. Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten-year period. Br J Cancer. 1986;53:175–180.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Loffler H, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood. 1984;64:38–47.
   PubMed Web of Science ®Google Scholar
• Durrant IJ, Richards SM. Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: report from the Medical Research Council Working Party on Adult Leukaemia. Br J Haematol. 1993;85:84–92.
   PubMed Web of Science ®Google Scholar
• Radford JE, Jones MP, Gigrich RD, et al. Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol. J Clin Oncol. 1989;7:58–66.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel H, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123–131.
   PubMed Web of Science ®Google Scholar
• Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol. 1991;9:2002–2015.
   PubMed Web of Science ®Google Scholar
• Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 1989;73:57–63.
   PubMed Web of Science ®Google Scholar
• Ludwig WD, Rieder H, Bartram CR, et al. Immunopheotypic and genotypic features, clinical characteristics and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898–1909.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Ortega JJ, Oriol A, et al. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Haematologica. 1998;83:222–230.
   Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Nagura E, Kimura K, Yamada K, et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 1994;33:359–365.
   PubMed Web of Science ®Google Scholar
• Rijneveld AW, van der Holt B, Daenen SM, et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25:1697–1703.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired theraphy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRALL-2003 study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843–1849.
   PubMed Web of Science ®Google Scholar
• Labar B, Suciu S, Willemze R, et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group. Haematologica. 2010;95:1489–1495.
   Web of Science ®Google Scholar
• Park Young K, Abuchowski A, Davis S, Davis F. Pharmacology of Escherichia coli L-asparaginase polyethylene glycol adduct. Anticancer Res. 1981;1:373–376.
   Web of Science ®Google Scholar
• Keating MJ, Holmes R, Lerner S, Ho DH. L-Asparaginase and PEG asparaginase-Padt, present, and future. Leuk Lymphoma. 1993;10:153–157.
   PubMedGoogle Scholar
• Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995;75:1176–1181.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sandord BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511. Blood. 2007;109:4164–4167.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Cortes J, Thomas D, Pierce S, Keating MJ, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene- glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1997;86:1203–1209.
   Web of Science ®Google Scholar
• Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukemia in first remission: a pilot study. Br J Hematol. 2003;123:836–841.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, Watkins K, Periclou AP, Avramis VI. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• Rytting M, Earl M, Douer D, Muriera B, Advani A, Bleyer A. Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase. Blood. 2008;112:Abstract 1924.
   Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A Randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children’s cancer group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009;53:162–167.
   PubMed Web of Science ®Google Scholar
• Freund M, Diedrich H, Ganser A, et al. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer. 1992;69:709–716.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in pediatric and adult patients with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–459.
   PubMed Web of Science ®Google Scholar
• Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparagines in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22:1665–1679.
   PubMed Web of Science ®Google Scholar
• Wenner KA, Pinheiro JP, Escherich G, et al. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005;217:321–326. German.
   PubMed Web of Science ®Google Scholar
• Dinnorf PA, Gootenbert J, Cohen M, Keegan P, Pazdur R. FDA drug approval summary: Pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia. Oncologist. 2007;12:991–994.
   Web of Science ®Google Scholar
• Nowak-Gotti U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22:103–114.
   Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488–1494.
   PubMed Web of Science ®Google Scholar
• Hernández-Espinosa D, Minano A, Ordonez A, et al. Dexamethasone induces a heat-stress response that ameliorated the conformational consequences on antithrombin of L-asparagines treatment. J Thromb Haemost. 2009;7:1128–1133.
   PubMed Web of Science ®Google Scholar
• Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antieoplastic asparaginases. Cancer Res. 1983;43:1602–1605.
   PubMed Web of Science ®Google Scholar
• Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2464–2471.
   PubMed Web of Science ®Google Scholar
• Chang J, Medlin S, Kahl B, et al. Augmented and standard BerlinFrankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49:2298–2307.
   PubMed Web of Science ®Google Scholar
• Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998;12:660–665.
   PubMed Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR- ABL negative acute lymphoblastic leukemia with a modified pediatric regimen. Br JHematol 2009;146:76–85.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:199–205.
   PubMed Web of Science ®Google Scholar